Clinical parameters affecting survival outcomes in patients with low-grade serous ovarian carcinoma: an international multicentre analysis
Taymaa May,Marcus Bernardini,Stephanie Lheureux,Katja K H Aben,Elisa V Bandera,Matthias W Beckmann,Javier Benitez,Andrew Berchuck,Line Bjørge,Michael E Carney,Daniel W Cramer,Anna deFazio,Thilo Dörk,Diana M Eccles,Michael Friedlander,María Jose García,Ellen L Goode,Alexander Hein,Claus K Høgdall,Allan Jensen,Sharon Johnatty,Catherine J Kennedy,Lambertus A Kiemeney,Susanne K Kjær,Jolanta Kupryjańczyk,Keitaro Matsuo,Valerie McGuire,Francesmary Modugno,Lisa E Paddock,Tanja Pejovic,Catherine M Phelan,Marjorie J Riggan,Cristina Rodriguez-Antona,Joseph H Rothstein,Weiva Sieh,Honglin Song,Kathryn L Terry,Anne M van Altena,Adriaan Vanderstichele,Ignace Vergote,Liv Cecilie Vestrheim Thomsen,Penelope M Webb,Nicolas Wentzensen,Lynne R Wilkens,Argyrios Ziogas,Haiyan Jiang,Alicia Tone,Katja K.H. Aben,Elisa V. Bandera,Matthias W. Beckmann,Michael E. Carney,Daniel W. Cramer,Diana M. Eccles,Ellen L. Goode,Claus K. Høgdall,Catherine J. Kennedy,Lambertus A. Kiemeney,Susanne K. Kjær,Lisa E. Paddock,Catherine M. Phelan,Marjorie J. Riggan,Joseph H. Rothstein,Kathryn L. Terry,Anne M. van Altena,Penelope M. Webb,Lynne R. Wilkens
DOI: https://doi.org/10.1503/cjs.017020
2023-06-27
Canadian Journal of Surgery
Abstract:BACKGROUND: Women with low-grade ovarian serous carcinoma (LGSC) benefit from surgical treatment; however, the role of chemotherapy is controversial. We examined an international database through the Ovarian Cancer Association Consortium to identify factors that affect survival in LGSC.METHODS: We performed a retrospective cohort analysis of patients with LGSC who had had primary surgery and had overall survival data available. We performed univariate and multivariate analyses of progression-free survival and overall survival, and generated Kaplan-Meier survival curves.RESULTS: Of the 707 patients with LGSC, 680 (96.2%) had available overall survival data. The patients' median age overall was 54 years. Of the 659 patients with International Federation of Obstetrics and Gynecology stage data, 156 (23.7%) had stage I disease, 64 (9.7%) had stage II, 395 (59.9%) had stage III, and 44 (6.7%) had stage IV. Of the 377 patients with surgical data, 200 (53.0%) had no visible residual disease. Of the 361 patients with chemotherapy data, 330 (91.4%) received first-line platinum-based chemotherapy. The median follow-up duration was 5.0 years. The median progression-free survival and overall survival were 43.2 months and 110.4 months, respectively. Multivariate analysis indicated a statistically significant impact of stage and residual disease on progression-free survival and overall survival. Platinum-based chemotherapy was not associated with a survival advantage.CONCLUSION: This multicentre analysis indicates that complete surgical cytoreduction to no visible residual disease has the most impact on improved survival in LGSC. This finding could immediately inform and change practice.
surgery